Augment Biologics key facts
- Operator of a biotechnology research company intended to develop a glycoprotein drug.
- It has raised $150K; the latest was Seed Round in Jan 2026.
- Notable investors include SOSV, IndieBio, University of California, MassBio, Merck Digital Sciences Studio — 6 tracked in total.
- Status: Privately Held (backing).
Who backs Augment Biologics
6- ·Watch Augment Biologics: the Monday email on marks, rounds and moves
Augment Biologics funding rounds
No funding rounds for Augment Biologics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Augment Biologics investors
6 investors are on record for Augment Biologics, including SOSV, IndieBio, University of California and MassBio.
About Augment Biologics
Operator of a biotechnology research company intended to develop a glycoprotein drug. The company offers AI-guided glyco templating for glycobiology, transforming biologic drug development, enabling the biopharmaceutical industry to enhance drug efficacy, safety, durability and manufacturing efficiency.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2021
- Website
- augmentbiologics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Augment Biologics doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.